Compare AstraZeneca plc (AZN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Trip.com Group Ltd — how do they compare? AstraZeneca plc trades at $166.95 (market cap $258.17B), while Trip.com Group Ltd trades at $42.77 (market cap $26.85B). The key difference: AstraZeneca plc is far larger — about 9.6× Trip.com Group Ltd's market cap, and AstraZeneca plc pays the higher dividend (1.87%). Which is the better fit depends on your goals.
| AZN | TCOM | |
|---|---|---|
Market Cap | $258.17B | $26.85B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $78.96 |
52-Week Low | $137.44 | $39.84 |
Enterprise Value | $284.41B | $19.55B |
Dividend Yield | 1.87% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TCOM trades at $42.36, down 1.03% on the day, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a P/E of 6.36, net income margin of 48.65%, and robust cash flow from operations of $19.63 billion in 2024. However, Q1 2026 earnings missed estimates, and Q2 revenue guidance of 3%-8% growth disappointed investors, contributing to recent price weakness.
The outlook is mixed; strong profitability and low valuation offer upside toward the $56.72 consensus price target, but near-term headwinds include regulatory scrutiny and muted guidance. Risks involve antitrust investigations and domestic travel dependency, yet institutional sentiment remains positive with 67% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
